User menu

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

Bibliographic reference McCrone, P ; Van den Bergh, Peter ; Chisholm, D ; Knapp, M. ; Hughes, R ; et. al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. In: European Journal of Neurology, Vol. 10, no. 6, p. 687-694 (2003)
Permanent URL
  1. Audet AM, Med Decis Making, 9, 324 (1989)
  2. Barber Julie A., Thompson Simon G., Analysis of cost data in randomized trials: an application of the non-parametric bootstrap, 10.1002/1097-0258(20001215)19:23<3219::aid-sim623>;2-p
  3. Beecham J, Measuring Mental Health Needs, 200 (2001)
  4. Bertorini Tulio E., Nance Adriana M., Horner Linda H., Greene William, Gelfand Michael S., Jaster J. Howard, Complications of intravenous gammaglobulin in neuromuscular and other diseases, 10.1002/(sici)1097-4598(199603)19:3<388::aid-mus20>;2-y
  5. Brannagan T. H., Nagle K. J., Lange D. J., Rowland L. P., Complications of intravenous immune globulin treatment in neurologic disease, 10.1212/wnl.47.3.674
  6. Briggs Andrew H., A BAYESIAN APPROACH TO STOCHASTIC COST-EFFECTIVENESS ANALYSIS An Illustration and Application to Blood Pressure Control in Type 2 Diabetes, 10.1017/s0266462301104071
  7. Chilcott J., Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis * Commentary: Evaluating disease modifying treatments in multiple sclerosis, 10.1136/bmj.326.7388.522
  8. Dalakas Marinos C., Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines, 10.1002/(sici)1097-4598(199911)22:11<1479::aid-mus3>;2-b
  9. Dolan P, A Social Tariff for EuroQol: Results from a UK General Population Survey (1995)
  10. Doorn P.A. v., Brand A., Strengers P.F.W., Meulstee J., Vermeulen M., High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study, 10.1212/wnl.40.2.209
  11. Dyck PJ, Ann Neurol, 11, 136 (1982)
  12. Dyck PJ, N Engl J Med, 314, 461 (1986)
  13. Espérou H., Jars-Guincestre M.-C., Bolgert F., Raphaël J.-C., Durand-Zaleski I., Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome, 10.1007/s001340051323
  14. Hahn AF, Brain, 119, 1067 (1996)
  15. Hughes Richard, Bensa Si�n, Willison Hugh, Van Den Bergh Peter, Comi Giancarlo, Illa Isabel, Nobile-Orazio Eduardo, Van Doorn Pieter, Dalakas Marinos, Bojar Martin, Swan Anthony, , Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy, 10.1002/ana.1088
  16. Lunn MPT, J Neurol Neurosurg Psychiatry, 66, 677 (1999)
  17. McLeod J. G., Pollard J. D., Macaskill P., Mohamed A., Spring P., Khurana V., Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia, 10.1002/1531-8249(199912)46:6<910::aid-ana14>;2-2
  18. Martin TD, Electroencephalogr Clin Neurophysiol Suppl, 50, 514 (1999)
  19. Mandel R.J., Effect of Acute l-Dopa Pretreatment on Apomorphine-Induced Rotational Behavior in a Rat Model of Parkinson's Disease, 10.1006/exnr.1999.7245
  20. Mooney C, Bootstrapping: a Non-Parametric Approach to Statistical Inference (1993)
  21. Nagpal Seema, Benstead Tim, Shumak Kenneth, Rock Gail, Brown Murray, Anderson David R., Treatment of Guillain-Barr� syndrome: A cost-effectiveness analysis, 10.1002/(sici)1098-1101(1999)14:3<107::aid-jca1>;2-3
  22. Netten A, Unit Costs of Health and Social Care (2001)
  23. Schulman Kevin, Burke Jennifer, Drummond Michael, Davies Linda, Carlsson Per, Gruger Jans, Harris Anthony, Lucioni Carlo, Gisbert Ramon, Llana Ted, Tom Eric, Bloom Bernard, Willke Richard, Glick Henry, Resource costing for multinational neurologic clinical trials: methods and results, 10.1002/(sici)1099-1050(1998110)7:7<629::aid-hec378>;2-n
  24. Sekul Elizabeth A., Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors, 10.7326/0003-4819-121-4-199408150-00004
  25. Stewart A., Sandercock J., Bryan S., Hyde C., Barton P. M., Fry-Smith A., Burls A., The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review, 10.3310/hta5020
  26. Veenstra DL, American Journal of Kidney Diseases, 33, 829 (1999)
  27. Williams A, The Role of the EUROQOL Instrument in QALY Calculations (1995)